Rallybio Corp (RLYB) stock
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)
Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –
Rallybio price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Rallybio's price to sales ratio was 129.8× on Nov 11, 2026, against 40.5× a year earlier.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 129.8× | +87.1 |
| 2025 | Dec 31, 2025 | 42.7× | – |
See a number that looks wrong?